BridgeMD
The efficacy of aprepitant for the prevention of postoperative nausea and vomiting after bariatric surgery.
EU CTIS ID: 2023-508849-40-00
What this study is testing
Decrease the incidence of postoperative nausea and vomiting.
- Therapeutic use (Phase IV)
A plain-language read of the study's public EU CTIS listing. The study team confirms the details.
Who can take part
You may be able to join if
- Patient is scheduled for bariatric surgery - LSG (laparoscopic sleeve gastrectomy),RYGB(Roux-en-Y) or OAGB(one-anastomosis MINI gastric bypass).
- Patients are adult - 18 years or older.
- Patients have at least 2 risk factors for PONV - female sex, non-smokers, post-operative opioid analgesia, previous PONV and a duration of surgery longer than 1 hour.
- Obesity with a BMI more than 30.
You likely can't join if
- Revision bariatric surgery.
- Known intolerance to the study drug - aprepitant.
The study team makes the final eligibility decision.
Questions & answers
Do participants get paid in this trial?
This listing doesn't specify compensation. Many trials still reimburse travel or offer a stipend, so it's worth asking the study team when you connect.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part - confirm specifics with the study team.
How long does this study last?
The listing doesn't state an exact length. The study team walks you through the schedule and number of visits before you decide to enroll.
Who can join this trial?
This study is enrolling all sexes, 65+ years, 18-64 years. The study team makes the final eligibility decision.
Explore other conditions
BridgeMD is an information and trial-matching tool - not medical advice, and not the study sponsor. Details come from EU CTIS; the study team decides eligibility.